NZ’s PHARMAC has agreed to
fund Revolade (eltrombopag), a
new drug for a rare and potentially
fatal blood disorder, idiopathic
thrombocytopenic purpura (ITP).
PHARMAC estimates that about
40 patients will receive the product
at a cost of $36,000 per patient per
year starting 01 Jan 2014.
And in other PHARMAC news, a
new agreement with GSK sees the
Special Authority criteria removed
from Seretide, and anti-viral
influenza treatment zanamavir
(Relenza) plus Revolade will be
listed while the price will reduce
on all three currently listed asthma
inhalers as a trade-off.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Dec 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.